Apr 30, 2013, 03.36 PM IST
Drug maker Aurobindo Pharma Ltd today said the company has received final approval from the US health regulator to manufacture and market Quinapril tablets in the American market.
The company has received the approval from the US Food and Drug Administration (USFDA) to manufacture the drug, which is indicated for the treatment of hypertension and falls under the cardiovascular (CVS) therapeutic category, in strengths of 5mg, 10mg, 20mg and 40mg (ANDA 202725), it said in a release.
The market size of the product is estimated to be USD 49 million for the 12 months ended September 2012, according to IMS, it said. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, it said. Aurobindo now has a total of 188 ANDA approvals (161 final approvals including 4 from Aurolife Pharma LLC and 27 tentative approvals) from USFDA, the release added. Shares of Aurobindo were quoting at Rs 187.70 apiece, down 2.24 per cent, in the late afternoon trade on the BSE.
Aurobindo Pharm stock price
On December 10, 2013, Aurobindo Pharma closed at Rs 306.70, up Rs 0.70, or 0.23 percent. The 52-week high of the share was Rs 312.00 and the 52-week low was Rs 127.15.
The company's trailing 12-month (TTM) EPS was at Rs 21.67 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 14.15. The latest book value of the company is Rs 100.93 per share. At current value, the price-to-book value of the company is 3.04.
Action in Aurobindo Pharma
Video of the day
Dec 10 2013, 11:21
- in FII View
Dec 4 2013, 11:08
- in FII View
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.